• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Cambridge Epigenetix appoints Professor Mark Dawson as Scientific Advisor

Cambridge Epigenetix appoints Professor Mark Dawson as Scientific Advisor

November 27, 2017
CenterWatch Staff

Cambridge Epigenetix, a pioneer in the development and application of epigenetic technologies, announced the appointment of epigenetics-based therapeutics specialist Professor Mark Dawson to its Scientific Advisory Board (SAB). Professor Dawson brings a wealth of experience in the translation of cancer epigenetics research to clinical practice. The appointment further strengthens CEGX’s panel of opinion leaders providing expert advice across the Company’s key focus areas of epigenetics, oncology, liquid biopsy, diagnostic and therapeutic development.

Mark Dawson, MBBS (Hons), BMedSci, FRACP, FRCPA, Ph.D., is Professor in the Sir Peter MacCallum Department of Oncology and Centre for Cancer Research at the University of Melbourne, where he is the Program Head of the Translational Hematology Program, Group Leader of the Cancer Epigenetics Laboratory and Consultant Hematologist in the Department of Hematology. Professor Dawson’s research is focused on epigenetic regulation in normal and malignant hematopoiesis and he is a leading expert on the development of targeted epigenetics-based therapeutics. He has helped to develop BET inhibitors, a novel epigenetic cancer therapy, which has entered early-phase clinical trials for patients with hematological cancers, and has significant experience in studying the role of epigenetic proteins in the initiation and maintenance of a range of malignancies. He completed his clinical training in Melbourne, Australia and was awarded the prestigious General Sir John Monash Fellowship and Cambridge Commonwealth Trust Fellowship, which he used to complete his PhD at the University of Cambridge.

Dr Jason Mellad, CEO at CEGX commented: “Innovation and scientific rigor are at the heart of what we do at CEGX, which is why we’ve appointed a panel of advisors consisting of several high-profile individuals who have a list of notable achievements across our key areas of interest, to aid us in maintaining these core values and continuing to drive the development of epigenetics-based technologies. Professor Dawson has significant research and clinical expertise in epigenetics, therapeutics and oncology so we are delighted he has agreed to join our SAB.”

Professor Mark Dawson, SAB Member commented: “CEGX is a pioneer in the field of epigenetics and I look forward to helping the Company harness the power of epigenetics to develop the next generation of diagnostics and therapeutics.”

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing